This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy.
The patient population will consist of adults men and women at least 18 years, who meet eligibility criteria. In this study propose combining tocilizumab with the standard treatment of azacitidine and venetoclax for patients with AML who are not eligible for intensive treatment.
First-line AML regardless of karyotype and molecular profile
ECOG <= 3
Patient eligible for chemotherapy combining azacitidine and venetoclax
Informed consent
LAM3
Patients eligible for intensive "3+7" treatment
Uncontrolled infection
Active and/or treated infection with Hep B, C, or HIV